Genetic Diagnostic Tests: A Growing Market
Filed in archive Diagnostics, Methodologies and Instrumentation , Genomics, Proteomics and Bioinformatics by ruth on April 17, 2006
and possibly identify a patient's response to certain therapies. Here are some of the companies offering such diagnostic tests:- Genomic Health offers Oncotype DX, which identifies estrogen-sensitive cancer patients, who are responsive to hormone therapy, as an alternative to chemotherapy. Price: $3,500
- XDx offers a AlloMap, blood test that gauges the probability of a patient rejecting a transplanted heart. Price: $3,000
- Myriad Genetics offers BRACAnalysis, a test for the risk of developing breast and ovarian cancer; COLARIS and COLARIS AP for hereditary colorectal and endometrial cancer; and MELARIS for inherited susceptibility to melanoma and pancreatic cancer. Price (BRACAnalysis): $3,000
- Monogram Biosciences offers HIV assays that help gauge which antiretroviral drugs are best to treat a particular AIDS patient. Price: $1,460
- Exact Sciences offers a DNA-based colorectal cancer screening. Cost: $500
- Aureon Laboratories conducts ProstatePx, a combination of tests and uses a computer algorithm to predict recurrence of prostate cancer. Price: $2,000
Permalink: Genetic Diagnostic Tests: A Growing Market
Tags:
cancer diagnostics tests biotech genetic diagnostic+tests genetic+diagnostic growing+market
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/20064
